Imikvimod (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Imikvimod" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

2^nd place

5^th place

4^th place

8^th place

11^th place

51^st place

399^th place

169^th place

68^th place

28^th place

1,581^st place

1,286^th place

low place

34^th place

18^th place

31^st place

doi.org

Schön MP, Schön M (december 2007). »Imiquimod: mode of action«. The British Journal of Dermatology. 157 (Suppl 2): 8–13. doi:10.1111/j.1365-2133.2007.08265.x. PMID 18067624. S2CID 36643157.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, in sod. (2013). »Aldara activates TLR7-independent immune defence«. Nature Communications. 4: 1560. Bibcode:2013NatCo...4.1560W. doi:10.1038/ncomms2566. PMID 23463003.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, in sod. (Februar 2002). »Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway«. Nature Immunology. 3 (2): 196–200. doi:10.1038/ni758. PMID 11812998. S2CID 1694900.
Bilu D, Sauder DN (november 2003). »Imiquimod: modes of action«. The British Journal of Dermatology. 149 (Suppl 66): 5–8. doi:10.1046/j.0366-077x.2003.05628.x. PMID 14616337. S2CID 41274637.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (Januar 1999). »Imiquimod applied topically: a novel immune response modifier and new class of drug«. International Journal of Immunopharmacology. 21 (1): 1–14. doi:10.1016/s0192-0561(98)00068-x. PMID 10411278.

»Imiquimod topical Use During Pregnancy«. Drugs.com. 29. maj 2019. Pridobljeno 14. julija 2020.
Drugs.com Drugs.com international listings for imiquimod Dostopano: 14. 6. 2015.

https://ec.europa.eu/health/documents/community-register/2006/2006090113748/anx_13748_sl.pdf, Povzetek glavnih značilnosti zdravila Aldara, Evropska agencija za zdravila, vpogled: 4. 4. 2024.
https://ec.europa.eu/health/documents/community-register/2012/20120823123822/anx_123822_sl.pdf, Povzetek glavnih značilnosti zdravila Zyclara, Evropska agencija za zdravila, vpogled: 4. 4. 2024.

Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, in sod. (2013). »Aldara activates TLR7-independent immune defence«. Nature Communications. 4: 1560. Bibcode:2013NatCo...4.1560W. doi:10.1038/ncomms2566. PMID 23463003.

Schön MP, Schön M (december 2007). »Imiquimod: mode of action«. The British Journal of Dermatology. 157 (Suppl 2): 8–13. doi:10.1111/j.1365-2133.2007.08265.x. PMID 18067624. S2CID 36643157.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, in sod. (2013). »Aldara activates TLR7-independent immune defence«. Nature Communications. 4: 1560. Bibcode:2013NatCo...4.1560W. doi:10.1038/ncomms2566. PMID 23463003.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, in sod. (Februar 2002). »Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway«. Nature Immunology. 3 (2): 196–200. doi:10.1038/ni758. PMID 11812998. S2CID 1694900.
Bilu D, Sauder DN (november 2003). »Imiquimod: modes of action«. The British Journal of Dermatology. 149 (Suppl 66): 5–8. doi:10.1046/j.0366-077x.2003.05628.x. PMID 14616337. S2CID 41274637.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (Januar 1999). »Imiquimod applied topically: a novel immune response modifier and new class of drug«. International Journal of Immunopharmacology. 21 (1): 1–14. doi:10.1016/s0192-0561(98)00068-x. PMID 10411278.

Schön MP, Schön M (december 2007). »Imiquimod: mode of action«. The British Journal of Dermatology. 157 (Suppl 2): 8–13. doi:10.1111/j.1365-2133.2007.08265.x. PMID 18067624. S2CID 36643157.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, in sod. (Februar 2002). »Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway«. Nature Immunology. 3 (2): 196–200. doi:10.1038/ni758. PMID 11812998. S2CID 1694900.
Bilu D, Sauder DN (november 2003). »Imiquimod: modes of action«. The British Journal of Dermatology. 149 (Suppl 66): 5–8. doi:10.1046/j.0366-077x.2003.05628.x. PMID 14616337. S2CID 41274637.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)